SCHEDULE: Janus Henderson Boosts Lexeo Therapeutics Stake

Janus Henderson Group plc and its affiliate reported increased beneficial ownership in Lexeo Therapeutics, Inc., holding 11.1% and 6.2% of common stock respectively.

Summary

• Janus Henderson Group plc filed Amendment No. 5 to its Schedule 13G, updating its beneficial ownership in Lexeo Therapeutics, Inc.
• As of June 30, 2025, Janus Henderson Group plc beneficially owned 3,684,383 shares of Lexeo Therapeutics, Inc. common stock, representing 11.1% of the class.
• Janus Henderson Biotech Innovation Master Fund Ltd, an indirect subsidiary, beneficially owned 2,041,481 shares, representing 6.2% of the class.
• Both entities hold shared voting and dispositive power over their respective shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a significant and continued institutional investment, which is generally a positive signal of confidence, though it does not provide operational or financial performance data.

Positives

• Janus Henderson Group plc, a major institutional investor, continues to hold a significant 11.1% stake in Lexeo Therapeutics, indicating sustained confidence.
• Its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, also maintains a substantial 6.2% stake, reinforcing institutional interest in the company.
• The filing certifies that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, which can be viewed positively by current management.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional investment in the biotechnology sector, specifically in Lexeo Therapeutics, Inc. Large stakes by specialized funds like Janus Henderson Biotech Innovation Master Fund Ltd often signal confidence in a company's long-term prospects within its industry.

Stakeholder Impact

• Shareholders: The presence of a large institutional investor like Janus Henderson can provide stability and potentially attract further institutional interest, signaling confidence in the company's value.
• Management: Awareness of a significant shareholder can influence strategic decisions and corporate governance considerations.

Key Dates

Keywords

Lexeo Therapeutics, Janus Henderson, Biotech, Investment, Common Stock, SEC Filing, Schedule 13G, Beneficial Ownership, Institutional Investor